| Literature DB >> 30905073 |
Shutang Peng1,2,3, Guo-Liang Huang1,2,3, Nansong Xu1,2,3, Yan Lu1,2,3, Liuyan Zeng4, Xin Li5, Shengqun Luo1,2,3, Xiaoming Lyu6, Qiang Jiang5, Tong Li1,2,3, Zhiwei He1,2,3.
Abstract
Our previous work reported activating transcription factor 1 (ATF1) is a promotive factor of nasopharyngeal carcinoma (NPC) tumorigenesis. This study is to further explore the association between the human ATF1 rs11169571 polymorphism and the risk of NPC occurrence. The association between ATF1 rs11169571 and risk of NPC occurrence was investigated in clinical samples of 560 patients and 661 controls obtained from southern China with high incidence of NPC. The genotypes were detected by PCR-RFLP. The differential expression activity of alleles -T and -C was analyzed with CNE-2 and C666-1 cells by luciferase reporter assay. Our data suggested that the allelic frequency and genotypes were significantly different between patients and controls. Compared to the TT homozygote, the TC and CC genotypes have been shown to be significantly decreased in NPC patients (OR = 0.494, 95% CI = 0.387-0.629, P < 0.001 and OR = 0.556, 95% CI = 0.364-0.851, P = 0.007, respectively). Compared to the -T allele, the -C allele is a factor of decreased risk in NPC (OR = 0.642, 95% CI = 0.537-0.767, P < 0.001). Luciferase reporter activity revealed that the -T allele confers a higher expression activity than the -C allele in CNE2 cells and C666-1 cells. In conclusion, ATF1 rs11169571 which could affect the expression of ATF1 is associated with NPC risk.Entities:
Keywords: ATF1; microRNA; nasopharyngeal carcinoma; polymorphism; risk
Mesh:
Substances:
Year: 2019 PMID: 30905073 PMCID: PMC6488110 DOI: 10.1002/cam4.2022
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Figure 1PCR‐RLFP detection results for ATF1 rs11169571 genotyping
Characteristics of nasopharyngeal carcinoma patients and controls
| Characteristics | Patient | Control |
|
|---|---|---|---|
| Age mean | 47.38 ± 11.67 | 49.38 ± 15.60 | 0.159 |
| Age | |||
| <45 | 233 (41.6%) | 245 (37.1%) | 0.295 |
| ≥45 | 327 (58.4%) | 416 (62.9%) | |
| Gender | |||
| Male | 321 (57.3%) | 359 (54.3%) | 0.112 |
| Female | 239 (42.7%) | 302 (45.7%) | |
| Primary tumor extension | |||
| T1 + T2 | 52 (36.6%) | __ | __ |
| T3 + T4 | 90 (43.4%) | ||
| Lymph node status | |||
| N0 | 11 (7.7%) | __ | __ |
| N1 + N2 + N3 | 131 (92.3%) | ||
| Metastasis | |||
| No | 123 (86.6%) | __ | __ |
| Yes | 19 (13.4%) | ||
Genotype and allele distribution of ATF1 rs11169571 in patients and controls
| Polymorphism | Patient n (%) | Control n (%) |
| OR (95% CI) |
|---|---|---|---|---|
| Genotype | ||||
| TT | 330 (59%) | 282 (42.7%) | < 0.001 | |
| TC | 187 (33.3%) | 316 (47.8%) | ||
| CC | 43 (7.7%) | 63 (9.5%) | ||
| CC vs TT | 0.007 | 0.556 | ||
| TC vs TT | <0.001 | 0.494 | ||
| CC + TC vs TT | <0.001 | 0.506 | ||
| Allele | ||||
| T | 847 (75.6%) | 880 (66.6%) | <0.001 | 0.642 (0.537‐0.767) |
| C | 273 (24.4%) | 442 (33.4%) | ||
Data were calculated by unconditional logistic regression with adjustment for age and gender.
Association of genotype and clinicopathological parameters in NPC patientsa
| Genotype | ||||
|---|---|---|---|---|
| Characteristics | TT | TC | CC |
|
| Age | ||||
| <45 | 39 (60%) | 21 (32%) | 5 (8%) | 0.368 |
| ≥45 | 39 (50.6%) | 27 (35.1%) | 11 (14.3%) | |
| Gender | ||||
| Male | 55 (52.4%) | 36 (34.2%) | 14 (13.4%) | 0.362 |
| Female | 23 (62.2%) | 12 (34.4%) | 2 (5.4%) | |
| Primary tumor extension | ||||
| T1 + T2 | 28 (53.9%) | 17 (32.7%) | 7 (13.4%) | 0.819 |
| T3 + T4 | 50 (55.6%) | 31 (34.4%) | 9 (10%) | |
| Lymph node status | ||||
| N0 | 9 (81.8%) | 1 (9.1%) | 1 (9.1%) | 0.151 |
| N1 + N2 + N3 | 69 (52.6%) | 47 (35.9%) | 15 (11.5%) | |
| Metastasis | ||||
| No | 65 (52.9%) | 43 (34.9%) | 15 (12.2%) | 0.408 |
| Yes | 13 (68.4%) | 5 (26.4%) | 1 (5.2%) | |
Data available only in 142 cases.
Figure 2Luciferase activity of reporter gene expression driven by two alleles of ATF1 rs11169571, ***P < 0.001, compared to –T allele. A, in CNE2 cells; B, in C666‐1 cells